Clinical Trials Browser

Anemia, Refractory, with Excess of Blasts, Lymphoma, Myeloproliferative Disorders, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT05371808 2026-03-11

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

Recruiting

247 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03297606 2026-03-04

CAPTUR

Phase 2 Recruiting

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05108298 2026-03-02

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Phase NA Recruiting

400 enrolled

BreastCNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidOther hematologic neoplasmSarcoma

Bone Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Leukemia, Lymphoma, Melanoma, Sarcoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Pyloric Stenosis, Hypertrophic

NCT05289687 2026-03-02

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Phase 2 Recruiting

20 enrolled

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02402244 2026-02-27

Project: Every Child for Younger Patients With Cancer

Recruiting

75,000 enrolled

CNSDermatologicEndocrineLymphoidMyeloidNETSarcoma

Carcinoma in Situ, Ganglioneuroma, Lymphoproliferative Disorders, Melanoma, Myeloproliferative Disorders, Neoplasms, Pheochromocytoma, Central Nervous System Neoplasms, Nephroma, Mesoblastic, Desmoid Tumors, Neuroendocrine Tumors

NCT04851119 2026-02-24

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Phase 1/2 Recruiting

147 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

NCT04870944 2026-02-24

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Phase 1/2 Recruiting

63 enrolled

CNSLymphoid

Diffuse Intrinsic Pontine Glioma, Lymphoma

NCT02981628 2026-02-23

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

80 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

ACCELERATE

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

CAPTUR

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Project: Every Child for Younger Patients With Cancer

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

FINISH-HL

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

CHiR Therapy for Elderly DLBCL Intolerant to Chemo

HiR+X

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma

CAPCI

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

POLAR BEAR

MOGAT

Prognostic Significance of ctDNA in HL

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients